Therapeutic potential of inhibitory VEGF splice variants.
Antiangiogenesis by inhibition of vascular endothelial growth factor (VEGF) has recently been demonstrated to be an effective therapeutic mode in human cancer alongside surgery, radiotherapy and chemotherapy. The authors have recently discovered a family of inhibitory VEGF splice variants, which has led to the possibility of using these isoforms as antiangiogenic agents. The discovery, mechanism of action, preclinical evaluation, and the potential uses of these isoforms in future cancer therapy will be discussed herein.